0001140361-23-034995.txt : 20230718 0001140361-23-034995.hdr.sgml : 20230718 20230718161535 ACCESSION NUMBER: 0001140361-23-034995 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230714 FILED AS OF DATE: 20230718 DATE AS OF CHANGE: 20230718 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BINDER BRANT CENTRAL INDEX KEY: 0001133594 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-11460 FILM NUMBER: 231094428 MAIL ADDRESS: STREET 1: C/O TRUST CO OF THE SWEST STREET 2: 200 PARK AVE SUITE 220 CITY: NEW YORK STATE: NY ZIP: 01066 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Eterna Therapeutics Inc. CENTRAL INDEX KEY: 0000748592 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 311103425 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1035 CAMBRIDGE STREET STREET 2: SUITE 18A CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: (212) 582-1199 MAIL ADDRESS: STREET 1: 10531 4S COMMONS DRIVE STREET 2: SUITE 166-550 CITY: SAN DIEGO STATE: CA ZIP: 92127 FORMER COMPANY: FORMER CONFORMED NAME: Brooklyn ImmunoTherapeutics, Inc. DATE OF NAME CHANGE: 20210325 FORMER COMPANY: FORMER CONFORMED NAME: NTN BUZZTIME INC DATE OF NAME CHANGE: 20051230 FORMER COMPANY: FORMER CONFORMED NAME: NTN COMMUNICATIONS INC DATE OF NAME CHANGE: 19920703 4 1 form4.xml X0508 4 2023-07-14 0000748592 Eterna Therapeutics Inc. ERNA 0001133594 BINDER BRANT C/O ETERNA THERAPEUTICS INC. 1035 CAMBRIDGE STREET, SUITE 18A CAMBRIDGE MA 02141 true false 6.0% Senior Convertible Promissory Notes due 2028 2.86 2023-07-13 4 P 0 120000 120000 A 2023-07-14 2028-07-14 Common Stock 41958 120000 D Warrants (right to buy) 2.61 2023-07-13 4 P 0 83916 0.125 A 2023-07-14 2028-07-14 Common Stock 83916 83916 D The reporting person entered into a Securities Purchase Agreement with the Issuer on July 13, 2023, pursuant to which, on July 14, 2023, the reporting person acquired $120,000 principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due July 2028 (the "Notes") and (ii) 83,916 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $2.61 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant share) in accordance with Nasdaq rules. /s/ Brant Binder 2023-07-18